Integra Sends Spine Business Off To Sea
This article was originally published in The Gray Sheet
The company's spine business will be established as an independent company, SeaSpine, within the year to improve growth prospects for all of Integra's businesses, officials say. Analysts say it will give Integra a slight boost but worry a spin-off is riskier than selling the division.
You may also be interested in...
With its acquisition of TEI Biosciences, Integra expands its wound management portfolio and sales channels in advances of its planned diabetic foot ulcer product in 2016. The deal, along with the July 1-completed spin out of SeaSpine, fits with Integra's strategy to achieve high single-digit growth.
Despite ongoing economic pressures, the worldwide orthopedic market grew 3% in 2014, reaching $34.7 billion. Although consolidation continues to cause uncertainty and disruption in this space, manufacturers at this year’s AAOS meeting were upbeat about the future as they brace for changes in the competitive landscape, health care delivery, and reimbursement.
Product launches last week at the North American Spine Society annual meeting in San Francisco.